Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (5y) (2015 - 2026)
Ligand Pharmaceuticals (LGND) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 5.90 Bn | 5.12 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.55% |
| Dec 31, 2025 | 15.87% |
| Sep 30, 2025 | -27.30% |
| Jun 30, 2025 | 59.91% |
| Mar 31, 2025 | -20.57% |
| Dec 31, 2024 | 15.62% |
| Sep 30, 2024 | 24.07% |
| Jun 30, 2024 | -16.17% |
| Mar 31, 2024 | 33.02% |
| Dec 31, 2023 | 15.76% |
| Sep 30, 2023 | -25.46% |
| Jun 30, 2023 | -21.06% |
| Mar 31, 2023 | 7.54% |
| Dec 31, 2022 | 39.98% |
| Sep 30, 2022 | 46.87% |
| Jun 30, 2022 | -17.04% |
| Mar 31, 2022 | 11.00% |
| Dec 31, 2021 | 43.49% |
| Sep 30, 2021 | -43.73% |
| Jun 30, 2021 | -18.52% |